The role of alpha1-blockers in combination therapy for hypertension

International Journal of Clinical Practice

Volumn 54, Issue 1, 2000, Pages 36-41

  Zusman, R M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; LIPID; PRAZOSIN; TERAZOSIN;

BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; DIASTOLIC BLOOD PRESSURE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADRENERGIC ALPHA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DOXAZOSIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; PRAZOSIN;

EID: 0033983621     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Joint National Committee. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-2446.
2. Materson BJ, Reda DJ, Cushman WC. Department of veterans affairs single-drug therapy of hypertension study: revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995; 8: 189-192.
3. Stamler J. Blood pressure and high blood pressure: aspects of risk. Hypertension 1991; 18: 95-107.
4. Flack JM, Neaton J, Grimm R Jr et al. Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation 1995; 92: 2437-2445.
5. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
6. Wacber B, Brunner HR. Combination antihypertensive therapy: does it have a role in rational therapy? Am J Hypertens 1997; 10: 131S-137S.
7. MacConnachie A, Maclean D. Low dose combination antihypertensive therapy: additional efficacy without additional adverse effects? Drug Safety 1995; 12: 85-90.
8. Messerli FH, Michalewicz L. Cardiac effects of combination therapy. Am J Hypertens 1997; 10: 146S-152S.
9. Fulton B, Wagstaff A, Sorkin E. Doxazosin: an update of its clinical pharmacology and therapeutic applications in the treatment of hypertension and BPH. Drugs 1995; 49: 295-320.
10. Grimm R, Jr, Flack J, Grandits G et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 1996; 275: 1549-1556.
11. Feher M, Henderson A, Wadsworth J et al. Alpha-blocker therapy: a possible advance in the treatment of diabetic hypertension: results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects. J Hum Hypertens 1990; 4: 571-577.
12. Shionoiri H, Gotoh E, Ito T et al. Long-term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study. Am J Med Sci 1994; 307(suppl 1): S91-S95.
13. 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients. Metabolism 1995; 44: 673-676.
14. Fawzy A, Braun K, Lewis G et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-109.
15. Gillenwater J, Conn R, Chrysant S et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 1995; 154: 110-115.
16. Tammela T. Benign prostatic hyperplasia: practical treatment guidelines. Drugs Aging 1997; 10: 349-366.
17. Mauersberger H. Effect of prazosin on blood pressure and plasma lipids in patients receiving a beta-blocker and diuretic regimen. Am J Med 1984; 76: 101-104.
18. van der Veur E, ten Berge BS, Donker AJ et al. A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension. Eur J Clin Pharmacol 1985; 28: 507-511.
19. Kaneko Y. Double-blind comparison of urapidil and prazosin in the treatment of patients with essential hypertension. Drugs 1988; 35: 156-163.
20. Elliott HL, Meredith PA, Campbell L, Reid JL. The combination of prazosin and verapamil in the treatment of essential hypertension. Clin Pharmacol Ther 1988; 43: 554-560.
21. Kiss I, Farsang C. Nifedipine-prazosin interaction in patients with essential hypertension. Cardiovasc Drugs Ther 1989; 3: 413-415.
22. Chrysant SG. Experience with terazosin administered in combination with other antihypertensive agents. Am J Med 1986; 80: 55-61.
23. Holtzman JL, Kaihlanen PM, Rider JA et al. Concomitant administration of terazosin and atenolol for the treatment of essential hypertension. Arch Intern Med 1988; 148: 539-543.
24. 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings. Clin Ther 1994; 16: 490-504.
25. Cohen JD. Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents. Am Heart J 1991; 122: 919-925.
26. Black HR, Chrysant SG, Curry CL et al. Antihypertensive and metabolic effects of concomitant administration of terazosin and methyclothiazide for the treatment of essential hypertension. J Clin Pharmacol 1992; 32: 351-359.
27. Lindner UK, von Manteuffel GE, Stafunsky M. The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine. Am Heart J 1988; 116: 1814-1820.
28. Englert RG, Mauersberger H. A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy. Am Heart J 1988; 116: 1826-1832.
29. Searle M, Dathan R, Dean S et al. Doxazosin in combination with atenolol in essential hypertension: a double-blind placebo-controlled multicentre trial. Eur J Clin Pharmacol 1990; 39: 299-300.
30. Englert RG, Barlage U. The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers. Am Heart J 1991; 121: 311-316.
31. Troffa C, Manunta P, Dessi-Fulgheri P et al. Efficacy and tolerability of doxazosin alone or in combination with chlorthalidone in essential hypertension. Curr Ther Res 1994; 55: 22-31.
32. Maclean D, McDevitt DG. Doxazosin in 'resistant'hypertension. J Hum Hypertens 1990; 4(suppl 3): 50-51.
33. Black H, Sollins J, Garafalo J. The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled on other antihypertensive medications: a randomised, placebo-controlled study. Am J Hypertens 2000 (in press)
34. Nalbantgil S, Nalbantgil I, Onder R. Is there a potentiation effect between doxazosin and amlodipine in the treatment of essential hypertension? Am J Hypertens 2000 (in press).
35. Group HHR. Combined effect of doxazosin and pindolol on blood pressure control and lipid concentrations in patients with essential hypertension selected from general practice. J Hum Hypertens 1992; 6: 181-184.
36. Bainbridge A, Meredith P, Elliott H. A clinical pharmacological assessment of doxazosin and enalapril in combination. Br J Pharmacol 1993; 36: 599-602.
37. Stokes GS, Johnston HJ, Okoro EO et al. Comparative and combined efficacy of doxazosin and enalapril in hypertensive patients. Clin Exp Hypertens 1994; 16: 709-727.
38. 1-blockade and angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1991; 9(suppl): S362-S363.
39. Brown M, Dickerson J. Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension. J Hypertens 1995; 13: 701-707.
40. Rachmani R, Levi Z, Slavachevsky I et al. Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria: a randomized cross-over study. Nephron 1998; 80: 175-182.
41. Daae LN, Westlie L. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. Blood Press 1998; 7: 39-45.
42. Davis B, Cutler J, Gordon D et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9: 342-360.
43. Whitcroft IA, Thomas JM, Rawsthorne A et al. Effects of alpha and beta adrenoceptor blocking drugs and ACE inhibitors on long term glucose and lipid control in hypertensive non-insulin dependent diabetics. Horm Metab Res 1990; 22(suppl): 42-46.
44. Rosenthal J. Control of coronary heart disease risk factors with doxazosin as monotherapy and in combination therapy. Am Heart J 1988; 116: 1763-1766.
45. 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. J Hum Hypertens 1994; 8: 219-226.
46. Donnelly R, Elliot HL, Meredith PA et al. Combination of nifedipine and doxazosin in essential hypertension. J Cardiovasc Pharmacol 1992; 19: 479-486.
47. Andersson P, Lithell H. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Am J Hypertens 1996; 9: 323-333.
48. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol 1995; 168(supp): 7-12.